Cadila awaits Indian approval for VLP technology
Cadila Pharmaceuticals' (Cadila) plan to use virus-like particle (VLP) technology for the developmen
Reportedly, the DCGI has asked the company to provide additional information about the technology to be used for the development of the vaccine.
Surinder Singh, chief drug controller general of India, said: "We have not given approval to Cadila as they are using a new technology called VLP and theirs is the only vaccine that uses VLP technology right now. So the company needs to substantiate its credentials.
"We are still looking at the data they gave us and trials are also on in Mexico. It is being seen as new pathway for the vaccine, but on the other hand, we already have traditional vaccines so we need to be very cautious," the website reported.
Cadila has singed a joint venture with Novavax for the development of VLP technology-based vaccines.